Rashmi K Murthy, MD, MBE

Rashmi K Murthy, MD, MBE, is an Associate Professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center. She earned her medical degree and a Master’s in Bioethics, and her research focuses on HER2-positive breast cancer, leptomeningeal metastasis, and novel antibody-drug conjugates. Her recent work includes leading the TBCRC049 phase 2 trial of tucatinib-based therapy for HER2+ leptomeningeal disease, published in Nature Cancer, and investigating blood-brain barrier–permeable tyrosine kinase inhibitors. She has contributed to immune subtyping in the I-SPY2 trial and studies on racial disparities in neoadjuvant therapy. Her translational research integrates spatial immunofluorescence and pharmacology to optimize targeted treatments.